Tower Research Capital (TRC)’s LYRA THERAPEUTICS INC LYRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,191
| Closed | -$6.75K | – | 5373 |
|
|
2025
Q4 | $6.75K | Buy |
2,191
+1,657
| +310% | +$8.24K | ﹤0.01% | 4051 |
|
|
2025
Q3 | $3.48K | Sell |
534
-949
| -64% | -$6.96K | ﹤0.01% | 4498 |
|
|
2025
Q2 | $13.3K | Buy |
1,483
+428
| +41% | +$3.55K | ﹤0.01% | 3867 |
|
|
2025
Q1 | $6.66K | Buy |
1,055
+259
| +33% | +$2.42K | ﹤0.01% | 4024 |
|
|
2024
Q4 | $8.2K | Buy |
796
+494
| +164% | +$5.43K | ﹤0.01% | 4013 |
|
|
2024
Q3 | $3.89K | Buy |
302
+166
| +122% | +$2.44K | ﹤0.01% | 4745 |
|
|
2024
Q2 | $1.89K | Sell |
136
-42
| -24% | -$4.75K | ﹤0.01% | 5080 |
|
|
2024
Q1 | $55.5K | Buy |
178
+131
| +279% | +$34.9K | ﹤0.01% | 2206 |
|
|
2023
Q4 | $12.4K | Sell |
47
-88
| -65% | -$15.9K | ﹤0.01% | 4046 |
|
|
2023
Q3 | $26.4K | Buy |
135
+106
| +366% | +$19K | ﹤0.01% | 3123 |
|
|
2023
Q2 | $5.93K | Sell |
29
-170
| -85% | -$23.6K | ﹤0.01% | 4770 |
|
|
2023
Q1 | $20K | Buy |
199
+103
| +107% | +$12.8K | ﹤0.01% | 3429 |
|
|
2022
Q4 | $15K | Buy |
96
+26
| +37% | +$5.15K | ﹤0.01% | 3432 |
|
|
2022
Q3 | $17K | Buy |
70
+52
| +289% | +$15.4K | ﹤0.01% | 4072 |
|
|
2022
Q2 | $5K | Buy |
+18
| New | +$4.9K | ﹤0.01% | 5073 |
|
|
2022
Q1 | – | Sell |
-213
| Closed | -$47K | – | 6365 |
|
|
2021
Q4 | $47K | Buy |
213
+128
| +151% | +$41.1K | ﹤0.01% | 2813 |
|
|
2021
Q3 | $38K | Buy |
85
+57
| +204% | +$21.6K | ﹤0.01% | 3178 |
|
|
2021
Q2 | $11K | Buy |
28
+7
| +33% | +$3.19K | ﹤0.01% | 4327 |
|
|
2021
Q1 | $13K | Sell |
21
-17
| -45% | -$10.6K | ﹤0.01% | 4205 |
|
|
2020
Q4 | $21K | Sell |
38
-44
| -54% | -$24.8K | ﹤0.01% | 3838 |
|
|
2020
Q3 | $46K | Buy |
82
+66
| +413% | +$41K | ﹤0.01% | 3571 |
|
|
2020
Q2 | $9K | Buy |
+16
| New | +$11.7K | ﹤0.01% | 4058 |
|
Other funds holding LYRA
Tower Research Capital (TRC)'s LYRA Position: Q1 2026 in Review
Tower Research Capital (TRC) sold out of LYRA THERAPEUTICS INC (LYRA) in Q1 2026, closing a stake of 2,191 shares — an estimated $6.75K sold.
Tower Research Capital (TRC) first reported a position in LYRA in Q2 2020 and held it in 22 quarters. The position peaked at $55.5K in Q1 2024. 1 fund tracked by Wall St. Rank holds LYRA as of Q1 2026.
- Tower Research Capital (TRC) reported no remaining LYRA THERAPEUTICS INC position as of Q1 2026 after selling out during the quarter.
- Tower Research Capital (TRC) sold 2,191 LYRA THERAPEUTICS INC shares in Q1 2026, an estimated $6.75K.
- Tower Research Capital (TRC) first reported a position in LYRA THERAPEUTICS INC in Q2 2020 and held it in 22 quarters.
- Tower Research Capital (TRC)'s LYRA THERAPEUTICS INC position peaked at $55.5K in Q1 2024.
- 1 fund tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.